Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has received an average recommendation of “Buy” from the eleven analysts that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $21.33.
A number of research analysts have commented on VNDA shares. Piper Jaffray Companies set a $23.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. HC Wainwright set a $18.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. Oppenheimer Holdings, Inc. set a $21.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. Jefferies Group LLC reiterated a “buy” rating and issued a $21.00 price objective on shares of Vanda Pharmaceuticals in a research report on Thursday, May 25th. Finally, TheStreet raised shares of Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Friday, May 12th.
Several hedge funds and other institutional investors have recently made changes to their positions in VNDA. Legal & General Group Plc boosted its position in shares of Vanda Pharmaceuticals by 37.4% in the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 3,022 shares during the last quarter. Kopp Investment Advisors LLC purchased a new position in shares of Vanda Pharmaceuticals during the second quarter valued at approximately $196,000. Virginia Retirement Systems ET AL purchased a new position in shares of Vanda Pharmaceuticals during the first quarter valued at approximately $193,000. Capital Fund Management S.A. bought a new stake in Vanda Pharmaceuticals during the first quarter valued at approximately $195,000. Finally, AQR Capital Management LLC bought a new stake in Vanda Pharmaceuticals during the fourth quarter valued at approximately $223,000. Institutional investors own 90.84% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://stocknewstimes.com/2017/08/15/vanda-pharmaceuticals-inc-vnda-given-average-rating-of-buy-by-analysts-updated-updated-updated.html.
Shares of Vanda Pharmaceuticals (NASDAQ VNDA) traded up 0.93% during mid-day trading on Friday, hitting $16.25. 391,079 shares of the stock were exchanged. The stock’s market cap is $728.94 million. Vanda Pharmaceuticals has a one year low of $11.58 and a one year high of $18.00. The company has a 50-day moving average of $16.18 and a 200 day moving average of $14.76.
Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.18. The firm had revenue of $42.06 million during the quarter, compared to analyst estimates of $40.31 million. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. Vanda Pharmaceuticals’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.01 earnings per share. On average, equities analysts predict that Vanda Pharmaceuticals will post ($0.47) earnings per share for the current year.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
